Aktis Oncology (NASDAQ:AKTS) Announces Quarterly Earnings Results

Aktis Oncology (NASDAQ:AKTS) released its quarterly earnings data on Monday. The technology company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.01), FiscalAI reports. The firm had revenue of $3.23 million for the quarter, compared to the consensus estimate of $2.23 million.

Aktis Oncology Stock Down 1.4%

Shares of AKTS traded down $0.27 during trading on Wednesday, reaching $19.46. The company’s stock had a trading volume of 20,335 shares, compared to its average volume of 324,880. The business’s fifty day moving average price is $18.74. Aktis Oncology has a twelve month low of $14.72 and a twelve month high of $29.16.

Analyst Ratings Changes

Several equities analysts recently weighed in on AKTS shares. HC Wainwright lifted their target price on shares of Aktis Oncology from $30.00 to $33.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. TD Cowen assumed coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They issued a “buy” rating on the stock. Leerink Partners started coverage on Aktis Oncology in a research note on Tuesday, February 3rd. They set an “outperform” rating and a $31.00 price objective on the stock. JPMorgan Chase & Co. started coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They issued an “overweight” rating and a $30.00 target price for the company. Finally, William Blair assumed coverage on Aktis Oncology in a report on Wednesday, April 29th. They set an “outperform” rating on the stock. Six equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $32.00.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.